Orion Porfolio Solutions LLC Increases Stock Holdings in Stryker Corporation $SYK

Orion Porfolio Solutions LLC increased its stake in Stryker Corporation (NYSE:SYK) by 10.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,156 shares of the medical technology company’s stock after acquiring an additional 1,856 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Stryker were worth $7,974,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SYK. Thrivent Financial for Lutherans raised its position in shares of Stryker by 12.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 97,365 shares of the medical technology company’s stock worth $38,507,000 after purchasing an additional 10,975 shares during the last quarter. Claris Financial LLC lifted its stake in Stryker by 4.5% in the 2nd quarter. Claris Financial LLC now owns 766 shares of the medical technology company’s stock worth $303,000 after purchasing an additional 33 shares in the last quarter. MASTERINVEST Kapitalanlage GmbH purchased a new position in Stryker during the second quarter worth approximately $1,921,000. Hilltop Partners LLC raised its holdings in shares of Stryker by 12.7% during the 2nd quarter. Hilltop Partners LLC now owns 743 shares of the medical technology company’s stock worth $294,000 after acquiring an additional 84 shares during the period. Finally, Stance Capital LLC acquired a new position in Stryker in the 2nd quarter valued at about $4,141,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Up 0.4%

SYK stock opened at $355.34 on Tuesday. The stock has a market cap of $135.89 billion, a P/E ratio of 46.69, a PEG ratio of 2.51 and a beta of 0.89. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company’s 50 day moving average is $366.60 and its two-hundred day moving average is $378.26.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the firm earned $2.87 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Wednesday, December 31st. Stryker’s dividend payout ratio is presently 44.15%.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent analyst reports. Truist Financial upped their price target on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research note on Friday, November 14th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 8th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $435.00 target price on shares of Stryker in a report on Friday, November 14th. Twelve investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $431.83.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares in the company, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 522,118 shares of company stock worth $185,381,932. 5.20% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.